Superluminal Raises $60M to Put Obesity Drug in Clinic

Superluminal Medicines closed an oversubscribed $60M Series B on September 3, 2026, financing the company's planned move from GPCR drug discovery into its first human study. BVF Partners led the round, with Deep Track Capital and Perceptive Advisors joining a returning syndicate that includes RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.

The money is intended to move Superluminal's oral, selective, biased MC4R agonist toward a Phase 1 trial in rare genetic forms of obesity and hypothalamic obesity by the end of 2026. It will also support additional pipeline programs and further development of the Boston company's Hyperloop discovery platform.

The broader test reaches beyond one obesity program. AI drug discovery companies can demonstrate faster modeling, better screening, and more detailed structural insight before a patient is ever dosed. Superluminal is approaching the point where those platform claims must translate into clinical execution, human safety, and eventually therapeutic evidence.

What Superluminal Medicines Raised

The $60M Series B was described by Superluminal as oversubscribed. BVF Partners led the financing, while Deep Track Capital and Perceptive Advisors participated as new investors. Returning investors include RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels. Fierce Biotech independently recorded the amount, round, syndicate, and intended Phase 1 use of proceeds.

Superluminal has now disclosed $213M across three financings. The company launched publicly with a $33M Seed round in August 2023 and closed a $120M Series A in September 2024 before adding the current Series B. No valuation was announced, and the company did not disclose the ownership purchased in the round, its exact runway, or a breakdown of spending by program.

That capital total should be kept separate from Superluminal's 2025 collaboration with Eli Lilly. Under that agreement, Superluminal is eligible to receive up to $1.3B through upfront and near-term payments, an equity investment, development and commercial milestones, and tiered royalties. The figure is contingent collaboration value rather than venture funding already received.

Why the MC4R Program Matters

Superluminal's lead program is an orally administered, selective, biased agonist of melanocortin-4 receptor, or MC4R. The pathway helps regulate appetite and energy balance and has established relevance in rare genetic obesity conditions, including Bardet-Biedl syndrome and hypothalamic obesity. Superluminal has also discussed potential future use in Prader-Willi syndrome and in combination with GLP-1 therapies, although those applications remain exploratory.

The company's design thesis is based on signaling bias. A receptor can trigger multiple downstream pathways, and Superluminal is trying to activate the pathways associated with therapeutic activity while reducing signaling tied to unwanted effects. The company reports high selectivity and a favorable safety profile in preclinical studies, but no human data has been generated. A planned Phase 1 study would begin answering the first clinical questions around dose, exposure, tolerability, and safety.

The distinction is important because the financing announcement describes a target, not a completed clinical transition. Superluminal expects the trial to begin by the end of 2026, but it has not published a protocol, candidate code, dosing schedule, enrollment target, or clinical registry record for the program. Investors are funding the work required to reach and operate that milestone.

How the Hyperloop Platform Works

Superluminal's Hyperloop platform combines structural biology, protein dynamics, machine learning, computational and medicinal chemistry, virtual screening, predictive ADME and toxicology, and experimental validation. The company initially focuses on G protein-coupled receptors, a large family of membrane proteins that control signaling throughout the body and remain central to many medicines.

The practical challenge is movement. Proteins do not hold one convenient shape while drug designers inspect them. Superluminal says its tools model ensembles of GPCR conformations, generate empirical cryo-EM structures, screen large molecular spaces, design compounds across different three-dimensional pockets, and predict properties that can derail a program later. Its current site says the team routinely generates dozens of proprietary high-resolution structures each month.

That workflow is intended to improve the starting quality and speed of small-molecule programs. It cannot remove the biological uncertainty that arrives in clinical development. The current pipeline lists the MC4R program alongside four additional undisclosed GPCR programs using biased ligands, multifunctional ligands, positive or negative allosteric modulators, and antagonists. The platform's commercial value will depend on whether that portfolio repeatedly produces compounds that survive development.

The People Moving the Platform Into the Clinic

Superluminal was co-founded by Cony D'Cruz and Ajay Yekkirala. D'Cruz is CEO, while Yekkirala is CSO and leads the scientific effort behind the GPCR pipeline. The current company page also lists Murco Ringnalda as CFO. No CTO is listed, so no technology executive title should be inferred from the company's AI work.

The Series B adds Harsha Paladugu of BVF Partners to Superluminal's board. Nandita Shangari of RA Capital Management remains a director and framed the returning and new investor mix as support for the company's ability to translate its platform into programs. The useful signal is less the quote than the syndicate's composition: specialist healthcare capital is now sitting beside technology investors and a pharmaceutical partner as Superluminal crosses into clinical development.

The Eli Lilly relationship gives the platform a second route to validation. Lilly has exclusive rights to develop and commercialize compounds from their collaboration after Superluminal delivers candidates that meet predefined criteria. Targets remain undisclosed, which limits outside evaluation, but the agreement places Superluminal's discovery system inside a commercial handoff with an experienced drug developer.

What This Round Changes

The Series B narrows the distance between Superluminal's platform promise and the evidence required to sustain it. The company has already shown that it can attract repeat financing, produce a multi-program pipeline, and secure a large partnership. The next layer is operational: complete IND-enabling work, open the Phase 1 study, dose patients, manage safety, and turn early clinical observations into decisions about the program.

For the AI drug discovery market, that handoff matters. Many platforms are evaluated through speed, model architecture, structure generation, or partnership economics because clinical data takes years to arrive. Once a company advances its own drug, the same platform can be judged through a harder chain of evidence. Discovery quality must survive manufacturing, toxicology, dosing, human biology, and clinical operations.

Superluminal's $60M gives the team room to make that passage while continuing to feed additional GPCR programs into the pipeline. The capital cannot compress the patient calendar. It can keep the company moving until the first human evidence begins to tell the platform which parts of its argument deserve to travel further.